AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37776326
Drug: CD19/22 dual-targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19/22 dual-targeted CAR-T cell combined with tislelizumab (anti-PD-1 antibody)
Trial: 37776754
Drug: Tablet-based neuroplasticity-oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based neuroplasticity-oriented sensorimotor training (EG)
Trial: 37776754
Drug: Tablet-based relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based relaxation training (CG)
Trial: 37776872
Drug: Daratumumab, carfilzomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy, administered as four 28-day cycles with daratumumab at 16 mg/kg intravenously on days 1, 8, 15, and 22, and carfilzomib at 56 mg/m2.
Trial: 37776872
Drug: Daratumumab, carfilzomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy.
Trial: 37776876
Drug: TV005 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV005 vaccine
Trial: 37776953
Drug: YK-029A 200
RxNorm normalized name: YK-4-279
DrugBank: YK-4-279 (DB17428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YK-029A 200 mg/d (dose-expansion phase)
Trial: 37776953
Drug: YK-029A (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YK-029A (all doses during dose-escalation)
Trial: 37777018
Drug: Ritlecitinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (200 mg loading dose/50 mg daily)
Trial: 37777018
Drug: Ritlecitinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (100 mg/50 mg daily)
Trial: 37777018
Drug: Ritlecitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (50 mg daily)
Trial: 37777018
Drug: Ritlecitinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (30 mg daily)
Trial: 37777018
Drug: Ritlecitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (10 mg daily)
Trial: 37777743
Drug: Empagliflozin (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (early treatment < 24 hours after PCI)
Trial: 37777743
Drug: Empagliflozin (intermediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (intermediate treatment 24 to < 48 hours after PCI)
Trial: 37777743
Drug: Empagliflozin (late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (late treatment 48 to 72 hours after PCI)
Trial: 37777832
Drug: Xevinapant 200
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xevinapant 200 mg/day on days 1-14 of a 3-week cycle
Trial: 37777832
Drug: Xevinapant 200
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xevinapant 200 mg/day
Trial: 37777827
Drug: Tremelimumab combined
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy
Trial: 37778226
Drug: Truncated dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Truncated dual antiplatelet therapy (DAPT)
Trial: 37778356
Drug: Gradual, flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual, flexible antipsychotic reduction
Trial: 37778358
Drug: Efgartigimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efgartigimod (10 mg/kg)
Trial: 37779885
Drug: Combined quantitative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined quantitative pupillometry with neuron-specific enolase (NSE >60 μg L)
Trial: 37779919
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) plus radiation therapy
Trial: 37780074
Drug: Dupilumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab treatment (discontinued)
Trial: 37780234
Drug: Reduced-dose pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose pneumococcal conjugate vaccine schedules
Trial: 37781132
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid dosage of 0.8 mg
Trial: 37781132
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid dosages ranging from 0 mg to 2.4 mg
Trial: 37781132
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid dosages of 0, 0.4, 0.6, 0.8, 1.2, 1.6, 2.0 mg to 2.4 mg
Trial: 37781158
Drug: Ibrutinib and
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib and bortezomib combination therapy
Trial: 37781158
Drug: Ibrutinib maintenance
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib maintenance after combination therapy
Trial: 37781159
Drug: MAMMS (two-way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAMMS (two-way SMS platform with MUAC tapes and weekly reminders)
Trial: 37781161
Drug: AZD3759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3759 at 200 mg bid
Trial: 37781161
Drug: AZD3759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3759 at 300 mg bid
Trial: 37781161
Drug: AZD3759 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3759 (both doses combined)
Trial: 37782145
Drug: MiniMed insulin
RxNorm normalized name: MiniMed Insulin Pump Reservoir 3 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MiniMed insulin pump therapy
Trial: 37782353
Drug: AG019 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG019 monotherapy (Phase 1b)
Trial: 37782353
Drug: AG019 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG019 in combination with teplizumab (Phase 2a)
Trial: 37782356
Drug: Serum UA
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum UA above 240 μmol/l
Trial: 37782421
Drug: Contrast-enhanced 2D
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced 2D T1-weighted gradient-echo sequences acquired at least 10 min after contrast injection (gadobutrol 0.1 mmol/kg)
Trial: 37782888
Drug: Intratumoral LSAM-PTX
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral LSAM-PTX (15 mg/mL)
Trial: 37783453
Drug: Cholera conjugate
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera conjugate vaccine (CCV) OSP:rTTHc
Trial: 37783805
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo drug response profiling
Trial: 37783805
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo resistance to chemotherapeutic drugs
Trial: 37783805
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo response to chemotherapy
Trial: 37783805
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo drug response profiles
Trial: 37783970
Drug: Elranatamab monotherapy
RxNorm normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab monotherapy
Trial: 37784053
Drug: EGYFIL™ topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGYFIL™ topical lotion
Trial: 37784109
Drug: Screening frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening frequency (once vs. at least twice daily)
Trial: 37784110
Drug: Enteral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L-citrulline (5 g every 12 hours for 5 days)
Trial: 37784197
Drug: Neuromuscular exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular exercise therapy program
Trial: 37786390
Drug: Metformin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (maximum dose, 2500 mg)
Trial: 37786396
Drug: Tirzepatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (5 mg, 10 mg, 15 mg)
Trial: 37786451
Drug: Tocilizumab 6
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 6 mg/kg
Trial: 37786451
Drug: Tocilizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (all doses)
Trial: 37786680
Drug: Zotiraciclib (ZTR),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotiraciclib (ZTR), a CDK9 inhibitor
Trial: 37787009
Drug: PEG-IFNa +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFNa + TDF (180 μg PEG-IFNa weekly plus 300 mg TDF once daily)
Trial: 37787009
Drug: PEG-IFNa +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFNa + placebo (180 μg PEG-IFNa weekly plus placebo)
Trial: 37787025
Drug: MAG-EPA (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAG-EPA (3.75 g daily)
Trial: 37787025
Drug: HOSO (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOSO (3.75 g daily)
Trial: 38845180
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) plus best medical management
Trial: 37787796
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment with cuff pressure 20 mm Hg (n=751)
Trial: 37787815
Drug: Integrative oncology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative oncology (IO) treatment program
Trial: 37787888
Drug: Fixed-ratio combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-ratio combination (basal insulin + GLP-1RA)
Trial: 37787888
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of basal insulin plus an SGLT-2 inhibitor (gliflo-combo)
Trial: 37787941
Drug: 5-alpha-reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-alpha-reductase inhibitors (5-ARIs)
Trial: 37787941
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (5-ARIs naïve)
Trial: 37788412
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg canakinumab once every 3 weeks for 18 cycles
Trial: 37788412
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg canakinumab
Trial: 37788924
Drug: MAC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAC treatment with macrolides, rifamycin, ethambutol, amikacin and/or fluoroquinolones
Trial: 37788924
Drug: Drug exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug exposure
Trial: 37790298
Drug: Neuromodulation (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulation (4 hours twice daily)
Trial: 38183154
Drug: Implementation strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation strategies focusing on training, education, clinician support, and tailoring physical therapy interventions for telehealth delivery and cultural competency
Trial: 37790451
Drug: Model combining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model combining time-on-treatment and rule-based volumes of CE and intratumoral Fluid
Trial: 37790490
Drug: ATL-DC +
RxNorm normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATL-DC + TLR agonist (poly-ICLC)
Trial: 37790490
Drug: ATL-DC +
RxNorm normalized name: ATL-104
DrugBank: ATL-104 (DB05670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATL-DC + TLR agonist (resiquimod)
Trial: 37790695
Drug: Oral-motor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-motor therapy programme for one month
Trial: 37791419
Drug: Rapid Antiretroviral
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Antiretroviral Therapy (ART) initiation after diagnosis of AHI
Trial: 37791765
Drug: pBI-11 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pBI-11 DNA vaccine via Tropis biojector
Trial: 37792065
Drug: Ruxolitinib (RUX)
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (RUX) administered according to the Summary of Product Characteristics
Trial: 37792612
Drug: Sarilumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab (200 mg, twice-monthly subcutaneous injection) plus a 14-week prednisone taper
Trial: 37792612
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus a 52-week prednisone taper
Trial: 37793101
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment, details on dosage and duration not available.
Trial: 37793306
Drug: Acupressure (ST25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure (ST25, CV12, CV6) for twice-daily therapy at 4 min per intervention for 7 days
Trial: 37793771
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin 2.5 mg/kg intravenously every 21 days
Trial: 37793771
Drug: Pomalidomide 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4.0 mg daily (days 1-21) and dexamethasone 40.0 mg weekly in a 28-day cycle
Trial: 37793853
Drug: SGN-B7H4V (vedotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-B7H4V (vedotin ADC) as monotherapy
Trial: 37793853
Drug: SGN-B7H4V (vedotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-B7H4V (vedotin ADC) in combination with anti-PD-1 agent
Trial: 37793919
Drug: Tele-prehabilitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-prehabilitation group using a tablet, two accelerometers, and a balance board (Khymeia, Padova, Italy)
Trial: 37794185
Drug: PTPN2/PTPN1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTPN2/PTPN1 inhibitor ABBV-CLS-484
Trial: 37794275
Drug: Oral Lichen
RxNorm normalized name: Lichen prunastri
DrugBank: Evernia prunastri (DB14172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Lichen Planus Symptom Severity Measure (OLPSSM)
Trial: 37794431
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (intradermal administration)
Trial: 37794472
Drug: ICS tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS tapering regimen (initial ICS dose reduced by 50% for 8 weeks followed by total ICS removal)
Trial: 37794472
Drug: ICS tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS tapering regimen
Trial: 37794659
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INCS) - 220 μg triamcinolone acetonide twice daily for 14 days prior to nasal allergen challenge (NAC)
Trial: 37794659
Drug: NAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC with no treatment intervention
Trial: 37794659
Drug: NAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC with 14 days pre-treatment with saline nasal spray (placebo)
Trial: 37794830
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment for bile acid diarrhoea
Trial: 37794830
Drug: C4 >
RxNorm normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C4 > 46 ng/mL
Trial: 37794830
Drug: Decision tree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision tree combining C4 ≥ 31 ng/mL with ≥1.1 daily watery stools (Bristol type 6 and 7)
Trial: 37794830
Drug: Logistic regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic regression model including C4, sum of measured stool bile acids, and daily watery stools
Trial: 37794845
Drug: AbobotulinumtoxinA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA treatment
Trial: 37794870
Drug: Daily prompts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily prompts to complete 10,000 steps
Trial: 37794870
Drug: Hourly prompts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly prompts to stand following inactivity
Trial: 37794870
Drug: Daily instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily instructions to read AHA guidelines
Trial: 37795521
Drug: Oral pre-exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine prescribed at baseline.
Trial: 37795883
Drug: Closed-Loop Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-Loop Insulin Delivery System
Trial: 37795976
Drug: ALVAC-HIV (vCP2438)
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B
Trial: 37795976
Drug: ALVAC-HIV (vCP2438)
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59
Trial: 37795976
Drug: ALVAC-HIV (vCP2438)
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with AS01B
Trial: 37796017
Drug: Telehealth group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Trial: 37796117
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with no injections (Control group)
Trial: 37796398
Drug: Fruquintinib 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 3 mg QD 3/1 (n=7)
Trial: 37796398
Drug: Fruquintinib 5
RxNorm normalized name: fruquintinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5 mg QD 3/1 (n=7)
Trial: 37796398
Drug: Fruquintinib 5
RxNorm normalized name: fruquintinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5 mg RP2D (n=6)
Trial: 37796417
Drug: ARR on
RxNorm normalized name: Barr Only CenterPointLock 2-Piece
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARR on interfering medications
Trial: 37796417
Drug: ARR off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARR off interfering medications
Trial: 37796417
Drug: ARR on
RxNorm normalized name: Barr Only CenterPointLock 2-Piece
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARR on interfering medications (threshold 10 pg/μIU)
Trial: 37796417
Drug: ARR off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARR off interfering medications (threshold 10 pg/μIU)
Trial: 37796513
Drug: Tislelizumab, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab, 200 mg intravenously every 3 weeks
Trial: 37796513
Drug: Sorafenib tosylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib tosylate, 400 mg orally twice daily
Trial: 37796540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CBN
Trial: 37796540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CBN + 10 mg CBD
Trial: 37796540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CBN + 20 mg CBD
Trial: 37796540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CBN + 100 mg CBD
Trial: 37797387
Drug: Capecitabine (Cap)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (Cap) 2000 mg/m² day 1-14 q3w for 6 cycles plus ibandronate (Ib) 50 mg p.o. daily or 6 mg intravenous q4w for 2 years
Trial: 37797632
Drug: Cadonilimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab at 6 mg/kg and 10 mg/kg every 2 weeks (dose escalation phase)